Abuse deterrent opioid/opioid-antagonist transdermal patch
AssigneeBuzzz Pharmaceuticals Limited
InventorsAudra Lynn Stinchcomb, Dana Carmel Hammell, Stan Lee Banks, Josh Eldridge, Miroslaw Jerzy Golinski
Life of this patent
Estimating the term…
Abstract
An abuse deterrent transdermal patch comprising a multilaminate. The multilaminate can comprise a first layer comprising an opioid analgesic compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable pressure sensitive adhesive. The multilaminate can further comprise a second layer comprising an opioid antagonist, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adhesive. In addition, the multilaminate can further comprise a barrier layer disposed between the first and second layers.
Claims21
A transdermal patch comprising a multilaminate, said multilaminate comprising:
- (i) a first layer comprising an opioid analgesic compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable pressure sensitive adhesive;
- (ii) a second layer comprising an opioid antagonist, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adhesive;
- and
- (iii) a barrier layer disposed between the first and second layers, and wherein the barrier layer substantially prevents the opioid antagonist diffusing from the second layer to the first layer during use, and wherein the barrier layer is a microporous ultra high density polyethylene (UHDPE) material;
- and wherein a proportion of the opioid antagonist in the second layer is present in the form of a pharmaceutically acceptable salt and a proportion of the opioid antagonist is present in a non-salt form.
Dependencies are inferred from the claim text.